Biotricity, Inc.
BTCY
$0.25
$0.00-1.40%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.47% | 19.51% | 18.12% | 14.31% | 14.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.47% | 19.51% | 18.12% | 14.31% | 14.09% |
| Cost of Revenue | -14.24% | -9.42% | -8.64% | -12.98% | -15.00% |
| Gross Profit | 27.08% | 29.99% | 28.57% | 26.43% | 29.40% |
| SG&A Expenses | -18.95% | -21.32% | -28.65% | -25.70% | -14.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.49% | -15.35% | -21.94% | -22.27% | -14.19% |
| Operating Income | 103.04% | 91.85% | 86.23% | 72.26% | 49.79% |
| Income Before Tax | 62.36% | 63.03% | 62.45% | 40.25% | 26.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.36% | 63.03% | 62.45% | 40.25% | 26.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.36% | 63.03% | 62.45% | 40.25% | 26.85% |
| EBIT | 103.04% | 91.85% | 86.23% | 72.26% | 49.79% |
| EBITDA | 103.18% | 91.94% | 86.30% | 72.31% | 49.83% |
| EPS Basic | 83.78% | 86.22% | 86.57% | 58.09% | 37.97% |
| Normalized Basic EPS | 80.93% | 83.42% | 84.46% | 72.74% | 52.53% |
| EPS Diluted | 83.75% | 86.20% | 86.56% | 58.08% | 37.97% |
| Normalized Diluted EPS | 80.93% | 83.42% | 84.46% | 72.74% | 52.53% |
| Average Basic Shares Outstanding | 52.12% | 88.15% | 140.10% | 142.58% | 99.48% |
| Average Diluted Shares Outstanding | 52.12% | 88.15% | 140.10% | 142.58% | 99.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.68% | -1.70% | -1.66% | -1.80% | -0.37% |